{"id":"NCT04181593","sponsor":"OmegaD LLC","briefTitle":"Phase 3 Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease","officialTitle":"A Randomized, Multicenter, Double-Masked, Placebo Controlled Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-11-18","primaryCompletion":"2021-02-28","completion":"2021-02-28","firstPosted":"2019-11-29","resultsPosted":"2024-07-29","lastUpdate":"2024-07-29"},"enrollment":322,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye"],"interventions":[{"type":"DRUG","name":"Omega 3 fatty acid","otherNames":["OmegaD Softgels"]},{"type":"DRUG","name":"Placebos","otherNames":["Placebo Softgels"]}],"arms":[{"label":"OmegaD","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a phase 3 study to evaluate the safety and efficacy of OmegaD softgels for the treatment of dry eye disease. A daily dose of 2 OmegaD softgels dosed orally BID will be compared to 2 placebo softgels (mineral oil ) dosed orally BID for 84 days. Approximately 300 subjects will be evaluated for their signs and symptoms of dry eye disease and for safety throughout the study.","primaryOutcome":{"measure":"Tear Osmolarity","timeFrame":"84 days","effectByArm":[{"arm":"OmegaD","deltaMin":13.4,"sd":17.1},{"arm":"Placebo","deltaMin":11.8,"sd":13.2}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":14,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":157},"commonTop":["Abdominal discomfort","Conjunctival hyperemia","Diarrhea","Dyspepsia","Influenza"]}}